Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Neupro
Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 6
HOS-114655 · Präparat HOS-094135
Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): domperidone (HOS-114656)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage 76df802be9e9f22d82e1b2e7d8d075ec263b75f2b3903e4b8515fd1ed554d94b · Zeichen 771–872 im Abschnitt
Wechselwirkungen · Neupro
Neupro 2 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 19–20
HOS-114682 · Präparat HOS-094135
19
Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): domperidone (HOS-114656)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage 853c306b2203ac6af381e6a834ffa623d21658b353891f983e0ab9b755fdfcfc · Zeichen 769–874 im Abschnitt
Wechselwirkungen · Neupro
Neupro 4 mg/24 h transdermal patch Neupro 6 mg/24 h transdermal patch Neupro 8 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 38
HOS-114718 · Präparat HOS-094135
Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): domperidone (HOS-114656)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage 76df802be9e9f22d82e1b2e7d8d075ec263b75f2b3903e4b8515fd1ed554d94b · Zeichen 716–817 im Abschnitt
Wechselwirkungen · Neupro
Neupro 2 mg/24 h 4 mg/24 h 6 mg/24 h 8 mg/24 h Transdermal patch · Abschnitt 4.5 · PDF-Seite 53
HOS-114742 · Präparat HOS-094135
Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): domperidone (HOS-114656)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage 76df802be9e9f22d82e1b2e7d8d075ec263b75f2b3903e4b8515fd1ed554d94b · Zeichen 716–817 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87–88
HOS-116581 · Präparat HOS-094447
87
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 27a092d7005e5ab0411f0babdff280e728008e3766038685e07864d1fc35a1d1 · Zeichen 2308–2745 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17–18
HOS-116378 · Präparat HOS-094447
17
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and
considerations PREZISTA dose adjustment of metformin is
co-administered with cobicistat is recommended in patients who are
expected to increase metformin plasma taking PREZISTA co-administered
concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for PREZISTA
co-administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended. When
Itraconazole and posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5307db9d59d8efdd7ae524944aa157f963cc375ad8c53e1296ceb7c11992bc47 · Zeichen 40055–42401 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116522 · Präparat HOS-094447
Concomitant use of PREZISTA Clinical monitoring is
co-administered with low dose ritonavir recommended when
and these antidepressants may increase co-administering PREZISTA with
concentrations of the antidepressant. low dose ritonavir with these
(CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
Amitriptyline may be needed.
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with PREZISTA
(induction of CYP450 enzymes) co-administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the
use of voriconazole.
Fluconazole Not studied. PREZISTA may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 22f4e74ad4f26762902abfc0033ac15b80ded8bd1a23d2f6a966a8c972097288 · Zeichen 30842–32867 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99–100
HOS-116613 · Präparat HOS-094447
99
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended.
Itraconazole and posaconazole, isavuconazole, When co-administration is
Posaconazole itraconazole or fluconazole may increase required the daily dose of
darunavir concentrations. itraconazole should not exceed
(CYP3A and/or P-gp inhibition) 200 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 13c8fc0fe58788a9eb15a4ab6e0e9fb34c04f3bc6ed970d671cb11cef0f8bb26 · Zeichen 40236–41872 im Abschnitt
Wechselwirkungen · Firdapse (previously Zenas)
FIRDAPSE 10 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210242 · Präparat HOS-154477
Based on the pharmacodynamic properties of amifampridine, the concomitant use with sultopride or
other medicinal products known to cause QT prolongation (e.g., disopyramide, cisapride,
domperidone, rifampicin and ketoconazole) is contraindicated as this combination may lead to an
enhanced risk of ventricular tachycardia, notably torsade de pointes (see sections 4.3 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) ketoconazole (HOS-084513) domperidone (HOS-114656) sultopride (HOS-085603) lead (HOS-085592) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-05-25T11:00:00Z · SHA-256 92cbbf47b9125cbf72b4c63d78ca50f05a820bbcbe9f450c757171186f057752 · Passage 3434802f5ad91e4e8e31d95af1adfc7e3de6817605d365c5f802fb206992ba5c · Zeichen 1852–2229 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 160 mg/20 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 4
HOS-123004 · Präparat HOS-095623
• Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
methadone, vinca alkaloids, arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): arsenic trioxide (HOS-109648) cisapride (HOS-085610) methadone (HOS-086198) bepridil (HOS-085612) droperidol (HOS-087801) domperidone (HOS-114656) diphemanil (HOS-085613) probucol (HOS-123007) levomethadyl (HOS-123008)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 56ead3e4fd74fc66e7c5a56aeda1018da64014846db730724b0c2840337b898a · Zeichen 1760–1907 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 19
HOS-123063 · Präparat HOS-095623
• Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
methadone, vinca alkaloids, arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): arsenic trioxide (HOS-109648) cisapride (HOS-085610) methadone (HOS-086198) bepridil (HOS-085612) droperidol (HOS-087801) domperidone (HOS-114656) diphemanil (HOS-085613) probucol (HOS-123007) levomethadyl (HOS-123008)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 6391a670f676f3cdeb59cdd10613c381f427adef0b6171fe1fe87156b2fc04d5 · Zeichen 1748–1893 im Abschnitt
Wechselwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-125464 · Präparat HOS-096073
Anti-arrhythmic medicinal products and other substances that may prolong QT
Bosutinib should be used with caution in patients who have or may develop prolongation of QT,
including those patients taking anti-arrhythmic medicinal products such as amiodarone, disopyramide,
procainamide, quinidine and sotalol or other medicinal products that may lead to QT prolongation
such as chloroquine, halofantrine, clarithromycin, domperidone, haloperidol, methadone, and
moxifloxacin (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) halofantrine (HOS-085606) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) bosutinib (HOS-109449) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage 88161ea85dfeb23e4b9e9c602a7dfea6a9d42372a9e1a9e087175c891fc2cac6 · Zeichen 4936–5427 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9
HOS-131702 · Präparat HOS-097124
In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used
with caution in patients who have or may develop prolongation of the QT interval, including those
patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide,
disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other
medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine,
halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the
QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) droperidol (HOS-087801) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 40eae0cde8e04371791e5e3fd69248b7ef61350ffe5b042411f9596daa975d64 · Zeichen 7488–8195 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131756 · Präparat HOS-097124
In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used
with caution in patients who have or may develop prolongation of the QT interval, including those
patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide,
disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other
medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine,
halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the
QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) droperidol (HOS-087801) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 40eae0cde8e04371791e5e3fd69248b7ef61350ffe5b042411f9596daa975d64 · Zeichen 7490–8197 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-132868 · Präparat HOS-097310
12
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Beta Blockers
Nadolol ↑in plasma concentrations of nadolol Careful monitoring. Dose adjustment
have been observed of nadolol may be required.
Calcium Channel
Blockers
Felodipine AUC: ↑ has been observed Contraindicated due to an increase
Nisoldipine Cmax: ↑ has been observed risk of edema and congestive heart
failure (see section 4.3).
Other dihydropyridines Potential ↑in plasma concentrations of Careful monitoring. Dose adjustment
Verapamil these drugs of dihydropyridines and verapamil
may be required.
Cardiovascular Drugs,
Miscellaneous
Ranolazine Ranolazine: Contraindicated due to the potential
AUC: ↑ 3.0 to 3.9-fold for serious cardiovascular events
including QT prolongation (see
section 4.3).
Bosentan Bosentan: Not recommended due to the
AUC: ↑ 2-fold potential for hepatic toxicity (see
Cmax: ↑ 2-fold section 4.3).
Aliskiren Aliskiren: Careful monitoring.
AUC: ↑ 1.8-fold Dose adjustment of aliskiren may be
required.
Diuretics
Eplerenone Eplerenone: Contraindicated due to the increased
AUC: ↑ 5.5-fold risk of hyperkalaemia and
hypotension (see section 4.3).
Gastrointestinal Drugs
Aprepitant Aprepitant: Careful monitoring.
AUC: ↑ 5-fold Dose adjustment of aprepitant
may be required
Domperidone Domperidone: Not recommended due to an
AUC: ↑ 3.0 fold increased risk in QT prolongation.
Cmax: ↑ 3.0 fold
Naloxegol Naloxegol Not recommended
AUC ↑ 12.9 fold
Cmax ↑ 9.6 fold
Immunosuppressants
Everolimus Everolimus: Contraindicated due to the large
Sirolimus (rapamycin) AUC: ↑ 15.3-fold increase in these medicinal products
Cmax: ↑ 4.1-fold concentrations (see section 4.3).
Sirolimus (rapamycin):
AUC: ↑ 10.9-fold
Cmax: ↑ 4.4-fold
Temsirolimus Temsirolimus: Not recommended unless necessary.
AUC: ↔ Careful monitoring and dose
Cmax: ↔ adjustment of these medicinal
Tacrolimus Ciclesonide active metabolite: products may be required.
Ciclosporine AUC: ↑ 3.5-fold
Budesonide
Ciclesonide Rest of drugs
↑in plasma concentrations of
these drugs have been observed
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): temsirolimus (HOS-117078) eplerenone (HOS-089050) felodipine (HOS-108908) aprepitant (HOS-112506) ciclesonide (HOS-132871) aliskiren (HOS-086927) domperidone (HOS-114656) nadolol (HOS-132869) calcium (HOS-085615) naloxegol (HOS-109428) budesonide (HOS-086332) tacrolimus (HOS-085202) nisoldipine (HOS-114251) everolimus (HOS-086310) sirolimus (HOS-085172) bosentan (HOS-086291) ranolazine (HOS-086141) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 55c1f47059932c9461c4dbc4909ce69dab602449f5d770f01d87bd752335918f · Zeichen 23587–27472 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-134441 · Präparat HOS-097580
Co-administration of darunavir with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) bepridil (HOS-085612) quinidine (HOS-085593) domperidone (HOS-114656) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0623acf1b29e890c85fc94e283370387704b0e29df5d70432cea48b4e0948b1f · Zeichen 452–1192 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 44–45
HOS-134581 · Präparat HOS-097580
44
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 29477591ae9b5ad89ec5266de4b7dbb3559f802d26c18cc2d6b3cb9400a9440c · Zeichen 2288–2741 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-134494 · Präparat HOS-097580
14
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are co-
20 mg once daily paroxetine Cmin ↓ 37% administered with darunavir with
paroxetine Cmax ↓ 36% low dose ritonavir, the
recommended approach is a dose
#
darunavir AUC ↔
titration of the antidepressant based
#
darunavir Cmin ↔
on a clinical assessment of
#
darunavir Cmax ↔
antidepressant response. In addition,
Sertraline sertraline AUC ↓ 49% patients on a stable dose of these
50 mg once daily sertraline Cmin ↓ 49% antidepressants who start treatment
sertraline Cmax ↓ 44% with darunavir with low dose
#
darunavir AUC ↔ ritonavir should be monitored for
#
darunavir Cmin ↓ 6% antidepressant response.
#
darunavir Cmax ↔
Clinical monitoring is
recommended when co-
Concomitant use of darunavir co- administering darunavir with low
administered with low dose ritonavir dose ritonavir with these
and these antidepressants may increase antidepressants and a dose
concentrations of the antidepressant. adjustment of the antidepressant
(CYP2D6 and/or CYP3A inhibition) may be needed.
Amitriptyline
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with darunavir co-
(induction of CYP450 enzymes) administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the use
of voriconazole.
Fluconazole Not studied. Darunavir may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may daily dose of itraconazole should
increase darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) sertraline (HOS-086247) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0e227ba8a8f0b79d0adea0b25305dcec4671959e568e634634a5edd206310734 · Zeichen 29798–33588 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.